16:50 Israel hits Pfizer vaccine and reports victory, protection rate reaches 99.995%



The Israeli people administered the second dose of Pfizer's Wuhan pneumonia vaccine, and the protection rate reached an alarming figure of 99.995%. Schematic diagram of Pfizer vaccine in Israeli medical institution.  (Associated Press)

The Israeli people administered the second dose of Pfizer’s Wuhan pneumonia vaccine, and the protection rate reached an alarming figure of 99.995%. Schematic diagram of Pfizer vaccine in Israeli medical institution. (Associated Press)

2021/01/26 16:50

[Real-time news/comprehensive report]Good news came out after Israel administered Pfizer’s Wuhan pneumonia (new coronavirus disease, COVID-19) vaccine to the public. The protection rate exceeded the 95% previously announced by Pfizer, reaching an alarming figure of 99.85%.

According to the “Times of Israel” report, the Maccabi Healthcare Services in Israel pointed out that 128,000 people received the second dose of the Wufei vaccine, and only 20 people were infected after one week, which was as low as 0.015%.

Immunologist Cyrille Cohen revealed that about 0.65% of Israel’s total population was diagnosed during the week. Therefore, although Maccabi’s data lacks a control sample, if the entire Israel is regarded as an imperfect control group, it is indeed higher than 95% effectiveness of Pfizer clinical trials.

Cohen said this exciting result confirms the high protection rate of Pfizer vaccine. Maccabi analyst Anat Ekka Zohar also said that although this is very early data, it is also very important information, because the world is learning how vaccines are effective through Israel.

For related news, see:

Please click here for the “Wuhan Pneumonia Special Zone” for more relevant information to take you first-hand.



No need to draw, no need to grab, watch the news with the app now, make sure to win prizes every day, I download the app and follow me to see the activity method

.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *